School of Pharmaceutical Sciences Shandong University, Jinan 250012, China
Tel/Fax: 86-531-88383781
Email: zhangj65@sdu.edu.cn
Present Position:
Professor of immunopharmaceutics
vice president of the School of Pharmaceutical Sciences, Shandong University
Deputy director of the institute of immunopharmacology and immunotherapy
Education Background:
2000.08-2003.06 Ph.D., Medical School of Shandong University, Jinan, China
1987.08-1990.07 M.S., Department of Pharmacology, Shandong Medical University, Jinan, China
1983.08-1987.07 B.S., Department of Pharmacology, Shandong Medical University, Jinan, China
Professional Experience:
2004.9-Date Professor, Deputy Director of the Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutic Science, Shandong University
2009.05-2009.11 Visitor, Harvard Medical School
2003.09-2006.06 Postdoctor, School of life science, The University of Science and Technology of China
2003.12-2004.09 Professor, Deputy Director of the Key Laboratory of Tumor Immunology and Medical Gene Engineering of Shandong, Jinan, China
1999.12-2003.12 Associate Professor, the Key Laboratory of Tumor Immunology and Medical Gene Engineering of Shandong, Jinan, China
1993.07-1999.12 Assistant Professor, the Institute of Basic Medicine, Shandong Academy of Medical Science, Jinan, China
1990.07-1993.07 Research Fellow, the Institute of Basic Medicine, Shandong Academy of Medical Science, Jinan, China
Teaching Courses:
Immunopharmacology, Immunobiology, Biopharmaceutics, Immunogene therapy
Research Interests:
(1) Cancer immunotherapy
(2) Innate immunity for anti-HBV infection
(3) Anti-HBV/anti-tumor vaccine
Research Grant Support:
Currently Active:
Nature and Science Fund of China, PI: Zhang J, 2012.01-2015.12, ￥520,000, The mechanisms of miRNAs associated with STAT3 in mediating tumor immune escape.
Nature and Science Fund of China, PI: Zhang J, 2010.1-2012.12, ￥320,000，The mechanisms of miRNAs regulating innate immunity in HBV infected hepatocytes.
National Mega Project on Major Infectious Diseases Prevention and Treatment, ￥680,000 2012.01-2015.12.
Grants Completed:
Nature and Science Fund of Shandong, PI: Zhang J, 1998.01-2000.12 ￥25,000, Correction of mutant N-ras gene by RNA-DNA chemic oligonuclestides.
Nature and Science Fund of China. PI: Tian ZG, Zhang J, 2000.01-2002.12, ￥130,000. The mechanisms of NK cell subsets for GVHD and GVL.
High-Tech Research and Development Program of China (863 program), PIs: Tian ZG, Zhang J(30% effort), 2002.11-2005.12, ￥600,000. The establishment of gene-modified NK cell lines and related study before their clinical application.
National Basic Research Program of China (973 program), PI: Zhang J, 2004.12-2009.12, ￥600,000, Immunological gene-therapy for severe diseases( Sub program: the application and basic research of decoy technology on diseases).
Nature and Science Fund of China. PI: Zhang J, 2006.01-2008.12, ￥210,000, Blocking tumor negative immuno-regulation by decoy ODNs targeting transcription factors.
Nature and Science Fund of China. PI: Zhang J, 2007.1-2009.12, ￥210,000, The finding of human “regulatory NK cells (NK-reg）” and their identification.
National Basic Research Program of China (973 program), PI: Zhang J, 2006.12-2011.12, ￥800,000, The Basic research for infection and immunity(Sub program：The effects and mechanisms of innate immunity in killing and clearance of pathogens.
Nature and Science Fund of China, PI: Wang LH, Zhang J (50%), 2007.1-2009.12, ￥400,000, Transcription factors and negative regulation for immune response.
High-Tech Research and Development Program of China (863 program) , PI: Zhang J, 2007-2012, ￥880,000 , Cellular and immunotherapy for severe diseases (Sub program：Gene modified NK cells)
Patents:
1. The establishment and techniques of IL-15 gene-modified NK cell line. CN1493687(2004-05)
2. The application of NKG2D ligands, CN200410096051.5
3. Expression vector for recombinant human HMBOX1 and the application of the antibody against HMBOX1, CN200910015258.8
Recent Publications:
Zhang X, Xiao W, Wang L, Tian Z, Zhang J*. Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One. 2011;6(6):e20965.
Su C, Hou Z, Zhang C, Tian Z, Zhang J*. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J. 2011 Jul 18;8:354.
Han Q, Zhang C, Zhang J, Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology. 2011 Oct;54(4):1179-89.
Wu L, Zhang C, Zhang J*. HMBOX1 negatively regulates NK cell functions by suppressing the NKG2D/DAP10 signaling pathway. Cell Mol Immunol. 2011 Sep;8(5):433-40.
Zhou Z, Zhang C, Xia C, Chen W, Zhu H, Shang P, Ma F, Wang PG, Zhang J, Xu W, Tian Z. Enhanced antitumor effects by chemical modified IGb3 analogues. Mol Cancer Ther. 2011 Aug;10(8):1375-84.
Wu L, Zhang C, Zheng X, Tian Z, Zhang J*. HMBOX1, homeobox transcription factor, negatively regulates interferon-γ production in natural killer cells. Int Immunopharmacol. 2011 Nov;11(11):1895-900.
Wu L, Zhang C, Tian Z, Zhang J*. NK cell-based approach for screening novel functional immune genes. Int Immunopharmacol. 2011 Feb;11(2):274-9.
Dai J, Zhang C, Tian Z, Zhang J*. Expression profile of HMBOX1, an novel transcription factor, in human cancers by high specific monoclonal antibodies. Experimental and Therapeutic Medicine, 2011, March 21，Volume 2 Number 3
Dai J, Wu L, Zhang C, Zheng X, Tian Z, Zhang J*. Recombinant expression of a novel human transcriptional repressor HMBOX1 and preparation of anti-HMBOX1 monoclonal antibody. Cell Mol Immunol. 2009 Aug;6(4):261-8.
Guotai Xu, Cai Zhang, Jian Zhang*. Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Mol Med Report 2009,2(5):819-824
Jian Zhang, Xiang Xiao, Wentao Liu, Gulcin Demirci and Xian C Li. Inhibitory Receptors of the Immune System: Functions and Therapeutic Implications. Cell Mol Immunol 2009 December; 6 (6): 407-414. Review
Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res. 2008 Oct 15;14(20):6432-
Chen Q, Wei H, Sun R, Zhang J, Tian Z. Therapeutic RNA Silencing of Cys-X3-Cys Chemokine Ligand 1 Gene Prevents Mice from Adenovirus Vector-induced Acute Liver Injury HEPATOLOGY 2008Feb;47:648-658.
Sun X, Zhang J*, Wang L, Tian Z, Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN, Cancer Letters, 2008Apri, 262:201-213
Zhang B, Zhang J*, Tian Z. Comparison in the effects of IL-2, IL-12, IL-15 and IFNa on gene regulation of granzymes of human NK cell line NK-92, Int Immunopharmacol, 2008 Jul;8(7):989-96.
Jiang W, Zhang J*, Tian Z. Functional characterization of the interleukin-15 gene transduction into human natural killer cell line (NKL), Cytotherapy, 2008;10(3):265-74.
* Corresponding author
Awards
2007.11 First grade Science and Technology Award by Anhui Provincial Government (4/5)
2007.12 First grade Chinese Medicine Science and Technology Advancement Award (4/11)
2008.12 Second grade National Award of Natural Science (4/5)
|
